Transcriptional Characterization Of The Tumor Immune Microenvironment And Its Prognostic Value For Locally Advanced Lung Adenocarcinoma In A Chinese Population

References

• Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10(7):990–1003.26134221
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.28055103
   PubMed Web of Science ®Google Scholar
• Hong QY, Wu GM, Qian GS, et al. Prevention and management of lung cancer in China. Cancer. 2015;121(Suppl 17):3080–3088.26331814
   PubMed Web of Science ®Google Scholar
• Li YX, Le Wang J, Gao M, Tang H, Gui R, Fu YF. Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer. Am J Cancer Res. 2016;6(7):1494.27508092
   PubMed Web of Science ®Google Scholar
• Chen Y, Peng X, Zhou Y, Xia K, Zhuang W. Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis. World J Surg Oncol. 2018;16(1):8.29338734
   PubMedGoogle Scholar
• Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) Edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.26762738
   PubMed Web of Science ®Google Scholar
• Zeng X, Li J, Peng L, et al. Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis. PLoS One. 2014;9(2):e88881.24586426
   PubMed Web of Science ®Google Scholar
• Xu L, Lei J, Wang Q, Li J, Wu L. Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations. Genet Mol Res. 2015;14(4):12973–12983.26505450
   PubMed Web of Science ®Google Scholar
• Shukla S, Evans JR, Malik R, et al. Development of a RNA-seq based prognostic signature in lung adenocarcinoma. J Natl Cancer Inst. 2017;109(1).
   PubMedGoogle Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306.22419253
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330.28102259
   PubMed Web of Science ®Google Scholar
• Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14(11):655–668.28653677
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Germain C, et al. Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers. Adv Immunol. 2016;130:95–190.26923001
   PubMed Web of Science ®Google Scholar
• Angelova M, Mlecnik B, Vasaturo A, et al. Evolution of metastases in space and time under immune selection. Cell. 2018;175(3):751–765.e716.30318143
   PubMed Web of Science ®Google Scholar
• Finotello F, Trajanoski Z. Quantifying tumor-infiltrating immune cells from transcriptomics data. Cancer Immunol Immunother. 2018;67(7):1031–1040.29541787
   PubMed Web of Science ®Google Scholar
• Robinson DR, Wu YM, Lonigro RJ, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548(7667):297–303.28783718
   PubMed Web of Science ®Google Scholar
• Gong Z, Chen J, Cheng JN, et al. Tumor microenvironment properties are associated with low CD68-positive cell infiltration and favorable disease-free survival in EGFR-mutant lung adenocarcinoma. Clin Lung Cancer. 2018;19(5):e551–e558.29628320
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.29141660
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218.27765066
   PubMed Web of Science ®Google Scholar
• Paluch BE, Glenn ST, Conroy JM, et al. Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. Oncotarget. 2017;8(2):3197–3205.27911273
   PubMedGoogle Scholar
• Conroy JM, Pabla S, Glenn ST, et al. Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors. J Mol Diagn. 2018;20(1):95–109.29061374
   PubMed Web of Science ®Google Scholar
• Morrison C, Pabla S, Conroy JM, et al. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. J Immunother Cancer. 2018;6(1):32.29743104
   PubMedGoogle Scholar
• Rahbar M, Naraghi ZS, Mardanpour M, Mardanpour N. Tumor-infiltrating CD8+ lymphocytes effect on clinical outcome of muco-cutaneous melanoma. Indian J Dermatol. 2015;60(2):212.
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci. 2005;102(51):18538–18543.16344461
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964. doi:10.1126/science.112913917008531
   PubMed Web of Science ®Google Scholar
• Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–1955. doi:10.1200/JCO.2010.30.503721483002
   PubMed Web of Science ®Google Scholar
• Seo AN, Lee HJ, Kim EJ, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109(10):2705–2713.24129232
   PubMed Web of Science ®Google Scholar
• Rashidian M, Ingram JR, Dougan M, et al. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med. 2017. doi:10.1084/jem.20161950.
   PubMed Web of Science ®Google Scholar
• Chen P-L, Roh W, Reuben A, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 2016;6:827–837.27301722
   PubMed Web of Science ®Google Scholar
• Li X, Gruosso T, Zuo D, et al. Infiltration of CD8(+) T cells into tumor cell clusters in triple-negative breast cancer. Proc Natl Acad Sci U S A. 2019;116:3678–3687.30733298
   PubMed Web of Science ®Google Scholar
• Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31:443–473.23298205
   PubMed Web of Science ®Google Scholar
• Martinez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res. 2015;21(22):5047–5056.26567364
   PubMed Web of Science ®Google Scholar
• Thommen DS, Koelzer VH, Herzig P, et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24:994–1004.29892065
   PubMed Web of Science ®Google Scholar
• Gordon SM, Chaix J, Rupp LJ, et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity. 2012;36(1):55–67.22261438
   PubMed Web of Science ®Google Scholar
• Platonova S, Cherfils-Vicini J, Damotte D, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 2011;71(16):5412–5422.21708957
   PubMed Web of Science ®Google Scholar
• Carrega P, Morandi B, Costa R, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells.. Cancer. 2008;112(4):863–875.18203207
   PubMed Web of Science ®Google Scholar
• Houghton AM, Rzymkiewicz DM, Ji H, et al. Neutrophil elastase–mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med. 2010;16(2):219.20081861
   PubMed Web of Science ®Google Scholar
• Nawa M, Osada S, Morimitsu K, et al. Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy. Anticancer Res. 2012;32(1):13–19.22213283
   PubMed Web of Science ®Google Scholar
• Wada Y, Yoshida K, Hihara J, et al. Sivelestat, a specific neutrophil elastase inhibitor, suppresses the growth of gastric carcinoma cells by preventing the release of transforming growth factor‐α. Cancer Sci. 2006;97(10):1037–1043.16918998
   PubMed Web of Science ®Google Scholar
• Wada Y, Yoshida K, Tsutani Y, et al. Neutrophil elastase induces cell proliferation and migration by the release of TGF-α, PDGF and VEGF in esophageal cell lines. Oncol Rep. 2007;17(1):161–167.17143494
   PubMed Web of Science ®Google Scholar
• Sato T, Takahashi S, Mizumoto T, et al. Neutrophil elastase and cancer. Surg Oncol. 2006;15(4):217–222.17320378
   PubMed Web of Science ®Google Scholar
• Treffers LW, Hiemstra IH, Kuijpers TW, van Den Berg TK, Matlung HL. Neutrophils in cancer. Immunol Rev. 2016;273(1):312–328.27558343
   PubMed Web of Science ®Google Scholar